MindWalk (NASDAQ:HYFT) Issues Quarterly Earnings Results

MindWalk (NASDAQ:HYFT) announced its quarterly earnings data on Monday. The company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.04), Zacks reports. MindWalk had a negative net margin of 89.65% and a negative return on equity of 92.61%. The company had revenue of $2.73 million for the quarter.

MindWalk Stock Up 1.9%

Shares of NASDAQ:HYFT traded up $0.03 during trading on Monday, hitting $1.33. The stock had a trading volume of 213,792 shares, compared to its average volume of 358,475. The company has a quick ratio of 2.72, a current ratio of 2.80 and a debt-to-equity ratio of 0.26. The company has a market capitalization of $62.12 million, a PE ratio of -6.05 and a beta of 0.82. The firm’s fifty day moving average is $1.38 and its 200 day moving average is $1.36. MindWalk has a 12 month low of $0.99 and a 12 month high of $2.99.

Analyst Upgrades and Downgrades

HYFT has been the subject of a number of recent analyst reports. HC Wainwright reiterated a “buy” rating on shares of MindWalk in a report on Monday, July 20th. Zacks Research cut MindWalk from a “hold” rating to a “strong sell” rating in a report on Tuesday, July 28th. Wall Street Zen upgraded MindWalk from a “sell” rating to a “hold” rating in a research report on Saturday, August 15th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of MindWalk in a research note on Wednesday, July 15th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $5.00.

About MindWalk

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation.